Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C.

As transcatheter aortic valve replacement edges toward being a consideration for younger, lower-risk patients, researchers are beginning to think not only about achieving good clinical outcomes during ...

ATLANTA -- For transcatheter aortic valve replacement (TAVR) candidates with a small aortic annulus, the two leading platforms offered differing hemodynamic valve performances despite being similarly ...

Medtronic is kicking off the nationwide rollout of the latest generation of its transcatheter aortic valve replacement system, the Evolut FX. The TAVR implant first received approval to treat aortic ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a ...

The latest generation of Medtronic’s transcatheter aortic valve replacement implant has passed the FDA’s muster. Like those that came before it, the new Evolut FX+ is placed through a minimally ...

Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), the SMall ...

The Medtronic CoreValve Evolut R transcatheter aortic valve replacement system has received FDA approval. Medtronic and Edwards Lifesciences continue the transcatheter aortic valve replacement (TAVR) ...

More and more medical studies show that heart issues in women are not only underdiagnosed but should be treated differently. A study Medtronic designed to test its Evolut TAVR (transcatheter aortic ...